Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.
Tromp J, Hage C, Ouwerkerk W, Sanders-van Wijk S, Svedlund S, Saraste A, Ljung Faxén U, Lagerstrom Fermer M, Gan LM, Lund LH, Shah SJ, Lam CSP. Tromp J, et al. Among authors: lagerstrom fermer m. Circulation. 2019 Oct 15;140(16):1359-1361. doi: 10.1161/CIRCULATIONAHA.119.042569. Epub 2019 Oct 14. Circulation. 2019. PMID: 31609659 Free PMC article. No abstract available.
Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF.
Faxen UL, Venkateshvaran A, Shah SJ, Lam CSP, Svedlund S, Saraste A, Beussink-Nelson L, Lagerstrom Fermer M, Gan LM, Hage C, Lund LH. Faxen UL, et al. Among authors: lagerstrom fermer m. J Card Fail. 2021 Jul;27(7):756-765. doi: 10.1016/j.cardfail.2021.02.005. Epub 2021 Feb 26. J Card Fail. 2021. PMID: 33647474 Free article.
Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.
Chandramouli C, Ting TW, Tromp J, Agarwal A, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson L, Lagerström Fermer M, Gan LM, Lund L, Shah SJ, Lam CSP. Chandramouli C, et al. Among authors: lagerstrom fermer m. Eur J Heart Fail. 2022 Apr;24(4):681-684. doi: 10.1002/ejhf.2435. Epub 2022 Jan 31. Eur J Heart Fail. 2022. PMID: 35060248 Free PMC article.
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF.
Michaëlsson E, Lund LH, Hage C, Shah SJ, Voors AA, Saraste A, Redfors B, Grove EL, Barasa A, Richards AM, Svedlund S, Lagerström-Fermér M, Gabrielsen A, Garkaviy P, Gan LM, Lam CSP. Michaëlsson E, et al. Among authors: lagerstrom fermer m. JACC Heart Fail. 2023 Jul;11(7):775-787. doi: 10.1016/j.jchf.2023.03.002. Epub 2023 May 3. JACC Heart Fail. 2023. PMID: 37140510 Free article. Clinical Trial.
Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.
Anttila V, Saraste A, Knuuti J, Jaakkola P, Hedman M, Svedlund S, Lagerström-Fermér M, Kjaer M, Jeppsson A, Gan LM. Anttila V, et al. Among authors: lagerstrom fermer m. Mol Ther Methods Clin Dev. 2020 Jun 1;18:464-472. doi: 10.1016/j.omtm.2020.05.030. eCollection 2020 Sep 11. Mol Ther Methods Clin Dev. 2020. PMID: 32728595 Free PMC article.
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction.
Prescott E, Pernow J, Saraste A, Åkerblom A, Angerås O, Erlinge D, Grove EL, Hedman M, Jensen LO, Svedlund S, Kjaer M, Lagerström-Fermér M, Gan LM. Prescott E, et al. Among authors: lagerstrom fermer m. Contemp Clin Trials Commun. 2020 Jul 30;19:100629. doi: 10.1016/j.conctc.2020.100629. eCollection 2020 Sep. Contemp Clin Trials Commun. 2020. PMID: 32875138 Free PMC article.
PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve.
Haraldsson I, Gan LM, Svedlund S, Torngren K, Westergren HU, Redfors B, Lagerström-Fermér M, Angerås O, Råmunddal T, Petursson P, Odenstedt J, Albertsson P, Erlinge D, Omerovic E. Haraldsson I, et al. Among authors: lagerstrom fermer m. Vasc Health Risk Manag. 2019 Aug 28;15:375-384. doi: 10.2147/VHRM.S209003. eCollection 2019. Vasc Health Risk Manag. 2019. PMID: 31695398 Free PMC article.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Nelander K, Lagerstrom-Fermer M, Amilon C, Michaëlsson E, Heijer M, Kjaer M, Russell M, Han D, Lindstedt EL, Whatling C, Gan LM, Ericsson H. Nelander K, et al. Among authors: lagerstrom fermer m. Clin Transl Sci. 2021 May;14(3):812-819. doi: 10.1111/cts.12859. Epub 2021 May 2. Clin Transl Sci. 2021. PMID: 32770730 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R. Gan LM, et al. Among authors: lagerstrom fermer m. Br J Clin Pharmacol. 2019 Apr;85(4):762-770. doi: 10.1111/bcp.13855. Epub 2019 Feb 18. Br J Clin Pharmacol. 2019. PMID: 30618054 Free PMC article. Clinical Trial.
30 results